← Back to Search

Unknown

ARD-101 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Aardvark Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female subjects, 18-75 years of age
Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up run-in visit (baseline)
Awards & highlights

Study Summary

This trial will study the safety and effectiveness of a new drug, ARD-101, for treating obesity in adults. The trial will last for 12 weeks and will enroll obese adults with a BMI of 30-45 kg/m2.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~screening, days 1, 15, and 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and screening, days 1, 15, and 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Relative Change in Body Weight (%)
Secondary outcome measures
Change in Blood Lipid Concentrations
Change in Hemoglobin A1c
Change in Waist Circumference
+1 more
Other outcome measures
Area under the Curve (AUC) of Serum Levels of Glucose, Insulin, and C-peptide during MMTT
Body Fat Percentage
Categorical Weight Loss
+11 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ARD-101Experimental Treatment1 Intervention
Dose 200 mg of ARD-101, twice daily for 28 days
Group II: Placebo ComparatorPlacebo Group1 Intervention
Placebo arm matching active arm ARD-101, 200 mg BID
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ARD-101
2021
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

Aardvark Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
42 Total Patients Enrolled
1 Trials studying Obesity
12 Patients Enrolled for Obesity
University of California, San DiegoOTHER
1,119 Previous Clinical Trials
1,521,509 Total Patients Enrolled
52 Trials studying Obesity
7,462 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What site did they apply to?
Altman Clinical and Translational Research Institute, University of California, San Diego
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

I would like to lose weight and manage metabolic syndrome/insulin resistance.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 1 Day
Most responsive sites:
  1. Altman Clinical and Translational Research Institute, University of California, San Diego: < 24 hours
Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Study to Evaluate ARD-101 in Adults With Obesity
2021. "Study to Evaluate ARD-101 in Adults With Obesity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05121441.
~6 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top